These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 37115693)
1. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693 [TBL] [Abstract][Full Text] [Related]
2. Aspirin and immunotherapy: a Faustian bargain? Goethe EA; Heimberger AB; Rao G J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115694 [TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8 Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721 [TBL] [Abstract][Full Text] [Related]
4. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
5. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development. Nayeb-Hashemi H; Desai A; Demchev V; Bronson RT; Hornick JL; Cohen DE; Ukomadu C Biochem Biophys Res Commun; 2015 Sep; 465(2):167-73. PubMed ID: 26225745 [TBL] [Abstract][Full Text] [Related]
6. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. Qian W; Zhao M; Wang R; Li H J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102 [TBL] [Abstract][Full Text] [Related]
7. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy. Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271 [TBL] [Abstract][Full Text] [Related]
8. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma. Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X Front Immunol; 2023; 14():1112672. PubMed ID: 36993960 [TBL] [Abstract][Full Text] [Related]
9. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231 [TBL] [Abstract][Full Text] [Related]
10. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047 [TBL] [Abstract][Full Text] [Related]
11. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma. Hua N; Chen A; Yang C; Dong H; He X; Ru G; Tong X; Zhou F; Wang S Mol Biol Rep; 2022 Aug; 49(8):7911-7919. PubMed ID: 35776395 [TBL] [Abstract][Full Text] [Related]
12. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response. Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642 [TBL] [Abstract][Full Text] [Related]
13. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Son Y; Shin NR; Kim SH; Park SC; Lee HJ Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373 [TBL] [Abstract][Full Text] [Related]
14. A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1. Zhang X; Zhu H; Zheng X; Jiao Y; Ning L; Zhou EM; Mu Y Front Immunol; 2021; 12():670626. PubMed ID: 33968077 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of USP7 enhances CD8 Sun LL; Zhao LN; Sun J; Yuan HF; Wang YF; Hou CY; Lv P; Zhang HH; Yang G; Zhang NN; Zhang XD; Lu W Acta Pharmacol Sin; 2024 Aug; 45(8):1686-1700. PubMed ID: 38589688 [TBL] [Abstract][Full Text] [Related]
16. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential. Liu XH; Qi LW; Alolga RN; Liu Q Int J Biol Sci; 2022; 18(1):292-300. PubMed ID: 34975333 [TBL] [Abstract][Full Text] [Related]
17. Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression. Wang J; Wei W; Tang Q; Lu L; Luo Z; Li W; Lu Y; Pu J Cancer Med; 2020 Oct; 9(19):7125-7136. PubMed ID: 32810392 [TBL] [Abstract][Full Text] [Related]
18. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related]
19. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion. Zhuang Q; Dai Z; Xu X; Bai S; Zhang Y; Zheng Y; Xing X; Hu E; Wang Y; Guo W; Zhao B; Zeng Y; Liu X Cancer Res; 2024 Feb; 84(3):405-418. PubMed ID: 37963197 [TBL] [Abstract][Full Text] [Related]
20. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma. Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]